gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AKBAHealthcarePharmaceuticals

Akebia Therapeutics, Inc. (AKBA)

$0.6947−4.28%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.73▼ 65.79% in range
Nov 3, 2025Low $0.56 · High $2.12Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Akebia Therapeutics closed at $0.69 on Nov 4, down 4.28%, 67.2% below its 52-week closing high. Volume of 11.6M shares was 1.34× its 20-day average (above normal).

Split-adjusted performance: -20.9% over one month, -53.1% over six months, -67.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $49.13M, down 21.4% from a year earlier, with a net margin of -18.1%.

Short interest was 23.1M shares at the Oct 15 settlement, up 2.6% from the prior report (8.7% of float, 3.0 days to cover).

Market cap$192.5M277.1M shares
Revenue · quarter$49.1M−21.4% YoY
Diluted EPS$-0.03—
P/E · TTM—P/S 0.9×
Net margin-18.1%Gross 78.8%
Dividend yieldNone
52-week range0.56 – 2.12−67.2% from high
Volume11.6M1.34× 20-day avg
Volatility · 60d72.3%Annualised
Short % of float8.7%3.0 days to cover
Net cash$106.0MCash $155.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −9.1%1M −20.9%3M −27.2%6M −53.1%YTD −56.9%1Y −67.2%3Y −17.9%5Y −74.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum23
Revenue growth29
Net margin57
Value (low P/E)—
Size47

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short23.1M+2.6% vs prior
Days to cover3.0Settled Oct 15
% of float8.7%
Short vol. 10d60.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AKBAAkebia Therapeutics$0.6947−4.28%−53.1%−21.4%−18.1%—$192.5M
TRDAEntrada Therapeutics$5.06+7.20%−68.4%−53.9%−4762.0%—$197.0MCompare
ALXOALX Oncology Holdings$1.36+5.43%−34.9%———$188.1MCompare
NAGENiagen Bioscience$2.52+6.78%−49.3%−4.3%3.2%12.5$199.4MCompare
BBOTBridgeBio Oncology Therapeutics$2.30−0.86%−72.4%———$184.4MCompare
UPBUpstream Bio$3.70+9.14%−59.7%−17.5%−5136.1%—$202.7MCompare
WHWKWhitehawk Therapeutics$3.17+2.26%−23.6%———$180.7MCompare
RNACCartesian Therapeutics$6.82+6.40%−18.2%−100.0%——$206.3MCompare
KROSKeros Therapeutics$10.830.00%−8.1%−100.0%——$214.7MCompare

News about Akebia Therapeutics

All news →

No recent articles focused on Akebia Therapeutics. 1 articles mention it in passing.

Quick answers

What does Akebia Therapeutics do?
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics.
What is AKBA's market cap?
$192.51M, based on the Nov 4 close of $0.69.
Does Akebia Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AKBA is sold short?
23.1M shares, 8.7% of float, as of Oct 15, 2026.
What sector is AKBA in?
Healthcare, in the Pharmaceuticals industry.

About Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

HQ: Cambridge, MA194 employeesListed Mar 20, 2014akebia.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology